View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
May 4, 2021

Coronavirus company news summary – Novavax expands Covid-19 vaccine study to adolescents – Covaxin found effective against key viral variants

By Chris Lo

Novavax has begun a paediatric expansion of its Phase III clinical trial for NVX-CoV2373, a recombinant protein vaccine candidate against the novel coronavirus. The paediatric arm of the PREVENT-19 trial will assess the safety, efficacy and immunogenicity of NVX-CoV2373 in roughly 3,000 adolescents aged 12-17 years across 75 centres in the US. The participants will be randomly allocated either the vaccine candidate or placebo in two doses within a gap of three weeks.

Biopharma company Ocugen has announced that a study by scientists at the Indian Council of Medical Research (ICMR)-National Institute of Virology demonstrated Covaxin’s potential efficacy against the UK, Brazil and Indian double mutant variants of the coronavirus. The study shows that Covaxin-vaccinated sera successfully neutralised the three key variants in an in-vitro plaque reduction neutralisation test. Ocugen is developing Bharat Biotech’s Covaxin for the US market.

Specialty life sciences company Revive Therapeutics has signed a research agreement with the University of California, San Francisco (UCSF) to study bucillamine in treating severe cases of Covid-19. The agreement will support laboratory research to assess the efficacy of bucillamine in pre-clinical models of coronavirus and design procedures to test the drug’s effectiveness in human trials. Bucillamine has previously been investigated for the treatment of rheumatoid arthritis and acute gout.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU